| GEL thousands | 2019 | 2020 | 2021 | 2022¹ | 2023 | 2024 |
|---|---|---|---|---|---|---|
| P&L Items | ||||||
| Revenue | Register | Register | Register | 10,283 | Register | Register |
| Adj. Operating Profit² | Register | Register | Register | 1,932 | Register | Register |
| Adj. EBITDA² | Register | Register | Register | 2,237 | Register | Register |
| Net Income | Register | Register | Register | 67 | Register | Register |
| Margins & Profitability Ratios (%) | ||||||
| Adj. Operating Profit Margin² | Register | Register | Register | 18.8% | Register | Register |
| Adj. EBITDA Margin² | Register | Register | Register | 21.8% | Register | Register |
| Net Income Margin | Register | Register | Register | 0.7% | Register | Register |
| Balance Sheet Items & Leverage | ||||||
| Total Assets | Register | Register | Register | 17,949 | Register | Register |
| Total Debt³ | Register | Register | Register | 14,450 | Register | Register |
| Total Debt³ / Adj. EBITDA² | Register | Register | Register | 6.46x | Register | Register |
| Total Equity | Register | Register | Register | 599 | Register | Register |
| ROAE | Register | Register | Register | 5.2% | Register | Register |
¹ The 2022 balance sheet is as restated in the 2023 filing: equity was reduced by ₾1.4M through a correction booked directly in equity, and the 2022 income statement was not restated. Operating cash flow (−₾7.0M) appears to include payments for the new hospital building: the filing shows ₾12.6M of additions to property, plant and equipment but only ₾0.2M of capital expenditure.
² Adj. Operating Profit has been adjusted to exclude non-recurring and one-time items. Adj. EBITDA is calculated by adding back D&A expenses to the adjusted operating profit.
³ Total debt includes lease liabilities, where applicable.